person · Reporting owner

SBLENDORIO GLENN

Disclosed activity across 5 companies

Tapewire entity: 36737
SEC CIK: 0001277478

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
4D Molecular Therapeutics, Inc.FDMT · Entity 2419	Director	June 17, 2026	June 18, 2026
Mineralys Therapeutics, Inc.MLYS · Entity 4432	Director	February 19, 2026	February 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

4D Molecular Therapeutics, Inc.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16	Direct	50,000	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 50,000 · Balance 50,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Filing footnotes · ownership attribution and instrument terms

F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Mineralys Therapeutics, Inc.

Report date February 19, 2026 · Filed February 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,200	Reported balance After 2026-02-19 transaction · row 1 1 source row Row 1 · 2026-02-19 · Grant · Acquired 6,200 · Balance 6,200 F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.06 · Expires 2036-02-19	Direct	8,300	Reported balance After 2026-02-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-19 · Grant · Acquired 8,300 · Balance 8,300 F2: The stock option vests in 12 substantially equal monthly installments following the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.

F2: The stock option vests in 12 substantially equal monthly installments following the date of grant.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMICUS THERAPEUTICS, INC.

Report date April 27, 2026 · Filed April 27, 2026

Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-04-27 transaction · row 1 1 source row Row 1 · 2026-04-27 · Disposition to issuer · Disposed 142,564 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 122,150 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2026-06-09	Direct	Reported balance After 2026-04-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2027-06-13	Direct	Reported balance After 2026-04-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-27 · Disposition to issuer · Disposed 16,236 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2029-06-27	Direct	Reported balance After 2026-04-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-27 · Disposition to issuer · Disposed 19,473 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04	Direct	Reported balance After 2026-04-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-04-27 · Disposition to issuer · Disposed 18,574 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10	Direct	Reported balance After 2026-04-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-04-27 · Disposition to issuer · Disposed 36,111 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09	Direct	Reported balance After 2026-04-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08	Direct	Reported balance After 2026-04-27 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06	Direct	Reported balance After 2026-04-27 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05	Direct	Reported balance After 2026-04-27 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 122,150 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).

F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.

F3: Each Option was fully vested.

F4: Each Option vested in full in connection with consummation of the Merger.

INTERCEPT PHARMACEUTICALS, INC.

Report date November 08, 2023 · Filed November 13, 2023

Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-11-08 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2023-11-08 · Other · Disposed 23,447 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-11-08 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08	Direct	Reported balance After 2023-11-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82	Direct	Reported balance After 2023-11-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17	Direct	Reported balance After 2023-11-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $210.36	Direct	Reported balance After 2023-11-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-11-08 · Disposition to issuer · Disposed 551 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $183.62	Direct	Reported balance After 2023-11-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-11-08 · Disposition to issuer · Disposed 1,750 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $145.22	Direct	Reported balance After 2023-11-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-11-08 · Disposition to issuer · Disposed 1,598 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $122.01	Direct	Reported balance After 2023-11-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-11-08 · Disposition to issuer · Disposed 2,036 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12	Direct	Reported balance After 2023-11-08 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-11-08 · Disposition to issuer · Disposed 2,748 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25	Direct	Reported balance After 2023-11-08 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74	Direct	Reported balance After 2023-11-08 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.

F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof

IVERIC bio, Inc.

Report date July 11, 2023 · Filed July 13, 2023

Section 16 reporting ended · disclosed 2023-07-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-07-11 transaction · row 1 1 source row Row 1 · 2023-07-11 · Disposition to issuer · Disposed 239,275 · Balance 0 F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-07-11 · Disposition to issuer · Disposed 23,750 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-07-11 · Disposition to issuer · Disposed 73,315 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-07-11 · Disposition to issuer · Disposed 94,500 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-07-11 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.27 · Expires 2023-10-23	Direct	Reported balance After 2023-07-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-07-11 · Disposition to issuer · Disposed 6,949 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.00 · Expires 2024-05-20	Direct	Reported balance After 2023-07-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-07-11 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.30 · Expires 2025-06-01	Direct	Reported balance After 2023-07-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-07-11 · Disposition to issuer · Disposed 7,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.90 · Expires 2026-03-31	Direct	Reported balance After 2023-07-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-07-11 · Disposition to issuer · Disposed 150,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2027-01-29	Direct	Reported balance After 2023-07-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-07-11 · Disposition to issuer · Disposed 260,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2027-12-18	Direct	Reported balance After 2023-07-11 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-07-11 · Disposition to issuer · Disposed 325,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2028-12-11	Direct	Reported balance After 2023-07-11 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2023-07-11 · Disposition to issuer · Disposed 133,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2029-12-08	Direct	Reported balance After 2023-07-11 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2023-07-11 · Disposition to issuer · Disposed 190,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.50 · Expires 2030-12-17	Direct	Reported balance After 2023-07-11 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2023-07-11 · Disposition to issuer · Disposed 293,150 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.83 · Expires 2031-12-16	Direct	Reported balance After 2023-07-11 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2023-07-11 · Disposition to issuer · Disposed 252,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.57 · Expires 2032-12-19	Direct	Reported balance After 2023-07-11 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2023-07-11 · Disposition to issuer · Disposed 300,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.

F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.

F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 11, 2023 Filed Jul 13, 2023 13:59 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerCommon Stock	239,275	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-080686 · tm2321002-7_4seq1.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. Read SEC document
June 22, 2023 Filed Jun 26, 2023 16:44 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionStock Option (right to buy) · Derivative	11,084	$0.00 Strike: $13.22	$0.00	Disclosure SEC source: 0001410939-23-000099 · wk-form4_1687812280.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,084 shares Expires 2023-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on July 9, 2013 under the Registrant's 2007 Stock Incentive Plan and vested in monthly increments for a period of 36 months from the date of the grant. Read SEC document
June 22, 2023 Filed Jun 26, 2023 16:44 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	11,084	$13.22	$146,486.14	Disclosure SEC source: 0001410939-23-000099 · wk-form4_1687812280.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 08, 2023 Filed Jun 12, 2023 21:37 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	30,474	$0.00 Strike: $12.62	$0.00	Disclosure SEC source: 0001209191-23-036418 · doc4.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,474 Underlying: Common Stock · 30,474 shares Expires 2033-06-08 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document
June 08, 2023 Filed Jun 12, 2023 21:37 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	8,584	$0.00	$0.00	Disclosure SEC source: 0001209191-23-036418 · doc4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,303 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document
May 24, 2023 Filed May 25, 2023 20:40 UTC	INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343	GrantOption to Purchase Common Stock · Derivative	12,547	$0.00 Strike: $9.17	$0.00	Disclosure SEC source: 0001104659-23-064845 · tm2317083-8_4seq1.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,547 Underlying: Common Stock · 12,547 shares Expires 2033-05-24 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document
May 24, 2023 Filed May 25, 2023 20:40 UTC	INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343	GrantCommon Stock	8,111	$0.00	$0.00	Disclosure SEC source: 0001104659-23-064845 · tm2317083-8_4seq1.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,558 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document
May 18, 2023 Filed May 19, 2023 21:13 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	15,000	$0.00 Strike: $3.32	$0.00	Disclosure SEC source: 0001209191-23-031103 · doc4.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the options were fully vested and exercisable as of the transaction date. Read SEC document
May 18, 2023 Filed May 19, 2023 21:13 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	15,000	$3.32	$49,800.00	Disclosure SEC source: 0001209191-23-031103 · doc4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2023 Filed Jan 4, 2023 18:34 UTC	IVERIC bio, Inc. ISEE · Entity 111416	SaleCommon Stock	17,447	$20.06	$349,986.82	Disclosure SEC source: 0001410939-23-000008 · wf-form4_167287522283174.xml · nonDerivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,191 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on January 2, 2023. F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $19.91 to $20.56 on January 3, 2023 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees. The Reporting Person undertakes to provide upon request by the staff of the Securities Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document
January 02, 2023 Filed Jan 4, 2023 18:34 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionRestricted Stock Units · Derivative	31,500	$0.00	$0.00	Disclosure SEC source: 0001410939-23-000008 · wf-form4_167287522283174.xml · derivative · entry 3 SBLENDORIO GLENN · CIK 0001277478 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,500 Underlying: Common Stock · 31,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F4 · derivative.exercise_date: On December 16, 2021, the Reporting Person was granted 126,000 restricted stock units, which vests with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026), subject to continued employment with the Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan. F4 · derivative.expiration_date: On December 16, 2021, the Reporting Person was granted 126,000 restricted stock units, which vests with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026), subject to continued employment with the Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan. Read SEC document
January 02, 2023 Filed Jan 4, 2023 18:34 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	31,500	$0.00	$0.00	Disclosure SEC source: 0001410939-23-000008 · wf-form4_167287522283174.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. Read SEC document
December 27, 2022 Filed Dec 29, 2022 16:50 UTC	IVERIC bio, Inc. ISEE · Entity 111416	GiftCommon Stock	30,000	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000152 · wf-form4_167235064050943.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,138 F1 · shares: On December 27, 2022, the Reporting Person gifted a total of 30,000 shares of Registrant's common stock to three trusts of which the Reporting Person's immediate family members are the sole trustees and sole beneficiaries. The Reporting Person does not share a primary residence with any of the trustees or beneficiaries of these trusts and does not have a reportable beneficial interest in these shares. Read SEC document
December 20, 2022 Filed Dec 22, 2022 18:56 UTC	IVERIC bio, Inc. ISEE · Entity 111416	GrantRestricted Stock Units · Derivative	150,000	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000150 · wf-form4_167175334409918.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2024, January 2, 2025, January 2, 2026 and January 2, 2027). F3 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2024, January 2, 2025, January 2, 2026 and January 2, 2027). Read SEC document
December 20, 2022 Filed Dec 22, 2022 18:56 UTC	IVERIC bio, Inc. ISEE · Entity 111416	GrantStock Option (right to buy) · Derivative	300,000	$0.00 Strike: $22.57	$0.00	Disclosure SEC source: 0001410939-22-000150 · wf-form4_167175334409918.xml · derivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest as follows: (1) no shares underlying the option shall vest unless, for a period of twenty consecutive trading days, the average closing sale price of the Registrant's common stock is equal to or exceeds 125% of the exercise price per share of such option (the "Performance Condition"), (2) subject to satisfaction of the Performance Condition, the option shall vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in equal monthly installments through the fourth anniversary of the grant date, and (3) such stock option shall be subject to "double-trigger" acceleration of vesting upon termination of employment following a change in control of the Registrant. Read SEC document
December 19, 2022 Filed Dec 20, 2022 19:02 UTC	IVERIC bio, Inc. ISEE · Entity 111416	SaleCommon Stock	19,457	$21.51	$418,520.07	Disclosure SEC source: 0001410939-22-000138 · wf-form4_167158096227025.xml · nonDerivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,138 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on December 18, 2022. F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $21.19 to $21.95 on December 19, 2022 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees. The Reporting Person undertakes to provide upon request by the staff of the Securities Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document
December 18, 2022 Filed Dec 20, 2022 19:02 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionRestricted Stock Units · Derivative	36,658	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000138 · wf-form4_167158096227025.xml · derivative · entry 3 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,314 Underlying: Common Stock · 36,658 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On December 18, 2020, the Reporting Person was granted an award of 146,630 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. F4 · derivative.expiration_date: On December 18, 2020, the Reporting Person was granted an award of 146,630 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. Read SEC document
December 18, 2022 Filed Dec 20, 2022 19:02 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	36,658	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000138 · wf-form4_167158096227025.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document
December 12, 2022 Filed Dec 13, 2022 21:01 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionRestricted Stock Units · Derivative	22,950	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000126 · wf-form4_167098326198515.xml · derivative · entry 4 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On December 12, 2018, the Reporting Person was granted 91,800 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment withthe Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan. F4 · derivative.expiration_date: On December 12, 2018, the Reporting Person was granted 91,800 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment withthe Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan. Read SEC document
December 12, 2022 Filed Dec 13, 2022 21:01 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	22,950	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000126 · wf-form4_167098326198515.xml · nonDerivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document
December 09, 2022 Filed Dec 13, 2022 21:01 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionRestricted Stock Units · Derivative	23,750	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000126 · wf-form4_167098326198515.xml · derivative · entry 3 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,750 Underlying: Common Stock · 23,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F3 · derivative.exercise_date: On December 9, 2019, the Reporting Person was granted an award of 95,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continuedemployment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. F3 · derivative.expiration_date: On December 9, 2019, the Reporting Person was granted an award of 95,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continuedemployment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. Read SEC document
December 09, 2022 Filed Dec 13, 2022 21:01 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	23,750	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000126 · wf-form4_167098326198515.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F2 · balance_after: This total includes 548 shares acquired by the Reporting Person on September 15, 2022, under the Registrant's 2016 Employee Stock Purchase Plan that were not previously reported. Read SEC document
November 02, 2022 Filed Nov 4, 2022 17:01 UTC	IVERIC bio, Inc. ISEE · Entity 111416	SaleCommon Stock	50,000	$23.01	$1,150,500.00	Disclosure SEC source: 0001410939-22-000110 · wf-form4_166759567938998.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,689 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. The sales reported on this Form 4 are the final shares to be sold under the above referenced Rule 10b5-1 trading plan. This plan is now terminated. F2 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $22.54 to $23.65 per share on November 2, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:12 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	45,423	$0.00 Strike: $8.55	$0.00	Disclosure SEC source: 0001209191-22-035852 · doc4.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,423 Underlying: Common Stock · 45,423 shares Expires 2032-06-09 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:12 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	12,671	$0.00	$0.00	Disclosure SEC source: 0001209191-22-035852 · doc4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,719 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document
May 25, 2022 Filed May 27, 2022 16:18 UTC	INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343	GrantOption to Purchase Common Stock · Derivative	12,790	$0.00 Strike: $16.82	$0.00	Disclosure SEC source: 0001104659-22-065913 · tm2217184-5_4seq1.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,790 Underlying: Common Stock · 12,790 shares Expires 2032-05-25 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document
May 25, 2022 Filed May 27, 2022 16:18 UTC	INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343	GrantCommon Stock	7,737	$0.00	$0.00	Disclosure SEC source: 0001104659-22-065913 · tm2217184-5_4seq1.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,447 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document
April 04, 2022 Filed Apr 6, 2022 18:11 UTC	IVERIC bio, Inc. ISEE · Entity 111416	SaleCommon Stock	50,000	$18.76	$937,805.00	Disclosure SEC source: 0001410939-22-000048 · wf-form4_164928306290708.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,689 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. For a full discussion regarding the details of the Rule 10b5-1 trading plan adopted by the Reporting Person, refer to the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the the Securities and Exchange Commission on March 30, 2022. Read SEC document
April 01, 2022 Filed Apr 1, 2022 19:03 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionStock Option (right to buy) · Derivative	40,756	$0.00 Strike: $2.94	$0.00	Disclosure SEC source: 0001410939-22-000040 · wf-form4_164885419748372.xml · derivative · entry 9 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 40,756 shares Expires 2027-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. F5 · derivative.exercise_date: This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document
April 01, 2022 Filed Apr 1, 2022 19:03 UTC	IVERIC bio, Inc. ISEE · Entity 111416	SaleCommon Stock	40,756	$17.50	$713,230.00	Disclosure SEC source: 0001410939-22-000040 · wf-form4_164885419748372.xml · nonDerivative · entry 6 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,689 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. F4 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.83 per share on April 1, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document
April 01, 2022 Filed Apr 1, 2022 19:03 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	40,756	$2.94	$119,822.64	Disclosure SEC source: 0001410939-22-000040 · wf-form4_164885419748372.xml · nonDerivative · entry 5 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. Read SEC document
March 31, 2022 Filed Apr 1, 2022 19:03 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionStock Option (right to buy) · Derivative	1,400	$0.00 Strike: $2.94	$0.00	Disclosure SEC source: 0001410939-22-000040 · wf-form4_164885419748372.xml · derivative · entry 8 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,756 Underlying: Common Stock · 1,400 shares Expires 2027-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. F5 · derivative.exercise_date: This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document
March 31, 2022 Filed Apr 1, 2022 19:03 UTC	IVERIC bio, Inc. ISEE · Entity 111416	SaleCommon Stock	1,400	$17.02	$23,828.00	Disclosure SEC source: 0001410939-22-000040 · wf-form4_164885419748372.xml · nonDerivative · entry 4 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,689 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.02 per share on March 31, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document
March 31, 2022 Filed Apr 1, 2022 19:03 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	1,400	$2.94	$4,116.00	Disclosure SEC source: 0001410939-22-000040 · wf-form4_164885419748372.xml · nonDerivative · entry 3 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. Read SEC document
March 30, 2022 Filed Apr 1, 2022 19:03 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionStock Option (right to buy) · Derivative	1,213	$0.00 Strike: $2.94	$0.00	Disclosure SEC source: 0001410939-22-000040 · wf-form4_164885419748372.xml · derivative · entry 7 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,156 Underlying: Common Stock · 1,213 shares Expires 2027-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. F5 · derivative.exercise_date: This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document
March 30, 2022 Filed Apr 1, 2022 19:03 UTC	IVERIC bio, Inc. ISEE · Entity 111416	SaleCommon Stock	1,213	$17.00	$20,625.85	Disclosure SEC source: 0001410939-22-000040 · wf-form4_164885419748372.xml · nonDerivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,689 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. F2 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.01 per share on March 30, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document
March 30, 2022 Filed Apr 1, 2022 19:03 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	1,213	$2.94	$3,566.22	Disclosure SEC source: 0001410939-22-000040 · wf-form4_164885419748372.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. Read SEC document
March 25, 2022 Filed Mar 29, 2022 19:44 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionStock Option (right to buy) · Derivative	18,775	$0.00 Strike: $2.94	$0.00	Disclosure SEC source: 0001410939-22-000031 · wf-form4_164859742561860.xml · derivative · entry 6 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,369 Underlying: Common Stock · 18,775 shares Expires 2027-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021. F4 · derivative.exercise_date: This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document
March 25, 2022 Filed Mar 29, 2022 19:44 UTC	IVERIC bio, Inc. ISEE · Entity 111416	SaleCommon Stock	18,775	$17.06	$320,301.50	Disclosure SEC source: 0001410939-22-000031 · wf-form4_164859742561860.xml · nonDerivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,689 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021. F2 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.28 per share on March 25, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document
March 25, 2022 Filed Mar 29, 2022 19:44 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	18,775	$2.94	$55,198.50	Disclosure SEC source: 0001410939-22-000031 · wf-form4_164859742561860.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021. Read SEC document
March 18, 2022 Filed Mar 22, 2022 16:43 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionStock Option (right to buy) · Derivative	3,479	$0.00 Strike: $2.94	$0.00	Disclosure SEC source: 0001410939-22-000023 · wf-form4_164798177973672.xml · derivative · entry 3 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,144 Underlying: Common Stock · 3,479 shares Expires 2027-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021. F4 · derivative.exercise_date: This stock option award was granted on December 19, 2017 and vests with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document
March 18, 2022 Filed Mar 22, 2022 16:43 UTC	IVERIC bio, Inc. ISEE · Entity 111416	SaleCommon Stock	3,479	$17.00	$59,145.09	Disclosure SEC source: 0001410939-22-000023 · wf-form4_164798177973672.xml · nonDerivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,689 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021. F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.01 per share on March 18, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document
March 18, 2022 Filed Mar 22, 2022 16:43 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	3,479	$2.94	$10,228.26	Disclosure SEC source: 0001410939-22-000023 · wf-form4_164798177973672.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021. F2 · balance_after: This total includes 556 shares acquired by the Reporting Person on March 15, 2022, under the Registrant's 2016 Employee Stock Purchase Plan that were not previously reported. Read SEC document
March 04, 2022 Filed Mar 7, 2022 22:54 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	15,000	$0.00 Strike: $4.79	$0.00	Disclosure SEC source: 0001209191-22-016793 · doc4.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the options were fully vested and exercisable as of the transaction date. Read SEC document
March 04, 2022 Filed Mar 7, 2022 22:54 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	15,000	$4.79	$71,850.00	Disclosure SEC source: 0001209191-22-016793 · doc4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 31, 2021 Filed Jan 3, 2022 17:58 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionStock Option (Right to Buy) · Derivative	801	$0.00 Strike: $2.94	$0.00	Disclosure SEC source: 0001104659-22-000502 · tm221330-1_4seq1.xml · derivative · entry 6 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,623 Underlying: Common Stock · 801 shares Expires 2027-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021. F3 · derivative.exercise_date: This option was granted on December 19, 2017 and vests with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document
December 31, 2021 Filed Jan 3, 2022 17:58 UTC	IVERIC bio, Inc. ISEE · Entity 111416	SaleCommon Stock	801	$17.01	$13,621.01	Disclosure SEC source: 0001104659-22-000502 · tm221330-1_4seq1.xml · nonDerivative · entry 4 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,133 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021. F2 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.02 per share on December 31, 2021. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document
December 31, 2021 Filed Jan 3, 2022 17:58 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	801	$2.94	$2,354.94	Disclosure SEC source: 0001104659-22-000502 · tm221330-1_4seq1.xml · nonDerivative · entry 3 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021. Read SEC document
December 30, 2021 Filed Jan 3, 2022 17:58 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionStock Option (Right to Buy) · Derivative	100	$0.00 Strike: $2.94	$0.00	Disclosure SEC source: 0001104659-22-000502 · tm221330-1_4seq1.xml · derivative · entry 5 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,424 Underlying: Common Stock · 100 shares Expires 2027-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021. F3 · derivative.exercise_date: This option was granted on December 19, 2017 and vests with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document
December 30, 2021 Filed Jan 3, 2022 17:58 UTC	IVERIC bio, Inc. ISEE · Entity 111416	SaleCommon Stock	100	$17.01	$1,701.00	Disclosure SEC source: 0001104659-22-000502 · tm221330-1_4seq1.xml · nonDerivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,133 F1 · kind: The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.